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inhibition lowered plasma TG concentrations in animals with 
diet-induced hypertriglyceridemia.  In summary, ApoC3 
is an important independent correlate of TG-rich lipoprotein 
concentrations in rhesus macaques consuming a high-fructose 
diet. ApoC3 is a promising therapeutic target for hypertri-
glyceridemia in patients with MetS and diabetes.—Butler, A. 
A., C. A. Price, J. L. Graham, K. L. Stanhope, S. King, Y-H. 
Hung, P. Sethupathy, S. Wong, J. Hamilton, R. M. Krauss, A. 
A. Bremer, and P. J. Havel. Fructose-induced hypertriglyceri-
demia in rhesus macaques is attenuated with fish oil or 
ApoC3 RNA interference. J. Lipid Res. 2019. 60: 805–818.
Supplementary key words diet effects/lipid metabolism • nutrition/
carbohydrate • nonhuman primate models • apolipoproteins • ribonu-
cleic acid interference • lipogenic enzymes • acetyl-coenzyme A carbox-
ylase • apolipoprotein C3
Elevation of cholesterol and/or triglycerides (TGs) in the 
circulation (dyslipidemia) is a frequent but modifiable risk 
factor for CVD (1, 2). Inhibition of cholesterol synthesis 
using HMG-CoA reductase inhibitors (statins) is considered 
a first line of treatment for dyslipidemias involving elevated 
levels of LDL cholesterol (LDL-C). However, effective treat-
ments for dyslipidemias in situations of statin-resistance 
or intolerance, or that involve severe hyperglyceridemia, 
Abstract Dyslipidemia and insulin resistance are signifi-
cant adverse outcomes of consuming high-sugar diets. 
Conversely, dietary fish oil (FO) reduces plasma lipids. Diet- 
induced dyslipidemia in a rhesus model better approximates 
the pathophysiology of human metabolic syndrome (MetS) 
than rodent models. Here, we investigated relationships 
between metabolic parameters and hypertriglyceridemia in 
rhesus macaques consuming a high-fructose diet (n = 59) 
and determined the effects of FO supplementation or RNA 
interference (RNAi) on plasma ApoC3 and triglyceride (TG) 
concentrations. Fructose supplementation increased body 
weight, fasting insulin, leptin, TGs, and large VLDL particles 
and reduced adiponectin concentrations (all P < 0.001). In 
multiple regression analyses, increased plasma ApoC3 was 
the most consistent and significant variable related to diet-
induced hypertriglyceridemia. FO supplementation, which 
attenuated increases of plasma TG and ApoC3 concentra-
tions, reversed fructose-induced shifts of lipoprotein particle 
size toward IDL and VLDL, a likely mechanism contributing 
to beneficial metabolic effects, and reduced hepatic expres-
sion of genes regulated by the SREBP pathway, particularly 
acetyl-CoA carboxylase. Furthermore, RNAi-mediated ApoC3 
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have been achieved using therapies targeting lipoprotein 
metabolism (3). These treatments have been aimed at mod-
ifying the transport of lipids in the circulatory and lymphatic 
systems, which is directed via trafficking in lipid-protein (li-
poprotein) complexes (2). Apolipoproteins possessing both 
hydrophobic and hydrophilic (amphipathic) properties 
are embedded in a membrane that surrounds a hydropho-
bic lipid core. Apolipoproteins situated in the outer mem-
brane act as ligands for cell-surface receptors that direct 
lipoprotein uptake to specific cell-types, and also regulate 
lipase-dependent release of TG (2).
ApoC3 is considered a highly promising candidate for 
treating severe hypertriglyceridemia (4, 5). Loss-of-func-
tion mutations in the APOC3 gene are associated with lower 
fasting and postprandial TG concentration, reduced LDL-C 
concentrations, increased HDL cholesterol (HDL-C) con-
centrations, and a substantially (40%) reduced risk of 
CVD (6–9). In contrast, transgenic mice overexpressing 
ApoC3 exhibit hypertriglyceridemia (10, 11). Clinical studies 
in which ApoC3 synthesis is suppressed by antisense oligo-
nucleotides (volanesorsen, Ionis 304801) have demonstrated 
substantial TG-lowering effects in patients with severe hy-
pertriglyceridemia (12, 13).
Incorporating fish oils (FOs) that are rich sources of the 
two major n-3 (-3) PUFAs, EPA and DHA, into the diet 
has long been implicated in a reduced risk for CVD (14). 
FOs as dietary supplements providing EPA alone, and in 
combination with DHA, reduced risk of CVD in several ran-
domized controlled trials (15). The anti-hyperlipidemic ac-
tions of FOs result from reduced de novo lipogenesis and 
hepatic production of VLDL cholesterol (VLDL-C) (16).
The current study extends our analysis of a nonhuman 
primate (rhesus macaque) model of diet-induced insulin 
resistance and dyslipidemia using nonhuman primates 
(rhesus macaques) (17). Nonhuman primates have a num-
ber of clear advantages over more commonly used rodent 
models of metabolic disease. They are more closely related 
evolutionarily and have metabolic physiology and lipid me-
tabolism that are more similar to that in humans (18, 19). 
Rhesus macaques provided with fructose-sweetened bever-
ages rapidly develop insulin resistance, hypertriglyceride-
mia, and inflammation (17). FO supplements prevent the 
concurrent increases of both plasma ApoC3 and TG con-
centrations in animals provided fructose-sweetened bever-
ages (20). In this study, we investigated the relationships 
between ApoC3 and dyslipidemia in a large cohort (n = 59) 
of rhesus macaques with fructose-induced dyslipidemia 
and insulin resistance. We also report results from this 
model investigating the effects of a novel RNA interference 
(RNAi) technology that targets ApoC3, and further ex-
plored the impact of FO supplementation on lipoprotein 
particle size distribution and the expression of genes in-
volved in hepatic lipid/lipoprotein metabolism.
MATERIALS AND METHODS
Rhesus macaques
Adult male rhesus macaques (n = 59) (age 12.0 ± 2.8 years, 
range 6.4–17.8) maintained at the California National Primate 
Research Center (CNPRC) were allowed ad libitum access to a 
standard commercial nonhuman primate diet (Advanced Proto-
col Old World Primate, LabDiet 5047) and water. This is primarily 
a grain-based diet that provides 30%/kcal as protein, 11%/kcal as 
fat, and 59%/kcal in the form of carbohydrates.
After determination of baseline body weight and collection of 
fasting blood samples, animals were provided a 15% fructose solu-
tion [75 g/day of fructose (300 kcal) in 500 ml/day of flavored 
Kool-Aid, Kraft Foods] for a 3 month time period. Male rhesus 
macaques consume on average 800–900 kcal/day, so these ani-
mals received approximately 30% of energy from fructose (17). 
Animals were weighed and fasting blood samples were collected 
again after 1 and 3 months of fructose consumption.
Ten additional adult male fructose-fed rhesus monkeys were 
supplemented with 4 g/day of whole FO (Jedwards, Inc., Brain-
tree, MA) for 6 months. The lipoprotein particle size results from 
these animals were compared with those from a subset of nine 
contemporaneously studied animals from the n = 59 group (20). 
Protocols for all the animal studies were approved by the Univer-
sity of California, Davis, Institutional Animal Care and Use Com-
mittee and were conducted in accordance with the US Department 
of Agriculture Animal Welfare Act and the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals.
ApoC3 RNAi study
The 20 animals used for these experiments received a modified 
moderate fat diet protocol and supplementation with high-fructose 
corn syrup (HFCS) in order to more closely match a human diet 
as well as maximize hypertriglyceridemia. Rhesus macaques re-
ceived HFCS-sweetened beverage (500 ml, 15% by weight sugar) 
twice per day, receiving a total of 150 g (600 kcal) of HFCS [55% 
fructose (330 kcal) and 45% glucose (270 kcal)] per day. These 
animals may have received up to 60% of their calories as sugar. 
These animals were maintained on New World monkey diet (Lab-
Diet 5040), which has a moderate fat content (23% kcal). 
Plasma samples (fasting) were collected at baseline. The animals 
were then started on the HFCS diet for 5 weeks. After 5 weeks on 
the moderate fat/HFCS diet, an RNAi trigger targeting APOC3 
mRNA (ARO-APOC3, 4 mg/kg) was administered in four animals 
via subcutaneous injection on day 0 and day 29 (n = 4). Two addi-
tional animals received vehicle injections.
ARO-APOC3 is a synthetic double-stranded (both strands con-
tain 21 nucleotides) hepatocyte-targeted N-acetylgalactosamine-
conjugated RNAi trigger molecule. The N-acetylgalactosamine 
moiety targets the RNAi triggers to hepatocytes by acting as a li-
gand for the highly expressed hepatocyte-specific asialoglycopro-
tein receptor. The RNAi trigger was designed to silence APOC3 
mRNA in humans and nonhuman primates with high specificity. 
The RNAi trigger was synthesized with 2′-O-methyl/2′-fluoro-
modified nucleotides to provide nuclease resistance and to abro-
gate potential immune activation (21). Fasting blood samples 
were then collected for the measurement of plasma ApoC3 and 
TG at days 8, 15, 21, 29, 36, 43, 50, 57, 71, and 85. Several nonfast-
ing blood samples were collected at baseline before the diet, prior 
to the RNAi or vehicle injections, and at days 7, 28, 56, and 84 
following the injections.
FO study
For the experiment comparing the effects of FO with control 
oil on hepatic gene expression, 14 animals were maintained on 
the same HFCS beverage regimen used for the ARO-APOC3 ex-
periment and provided a moderate fat (36% kcal) typical Amer-
ican diet (TestDiet, TAD #5L0P) specifically modified to have FO 
and fructose removed from the formulation. The animals were on 
the diet for 1.5–2.5 months prior to treatment. Animals were 
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selected to either receive 4 g/day of FO (Jedwards, Inc.) or 4 g/day 
of a control oil (BestBlend®; Wesson, Inc., Memphis, TN) contain-
ing a mixture of soybean and canola oils providing approximately 
40% of fat calories as polyunsaturated fat, 40% as monounsatu-
rated fat, and 10% as saturated fat for 4 weeks. Diet composition 
and certificates of analysis are provided as supplemental informa-
tion. The fish and control oil were stored in containers at 4°C 
under nitrogen gas to limit oxidation.
After 4 weeks of supplementation, the animals were anesthe-
tized with isoflurane and 10–15 small laparoscopic liver biopsy 
samples were taken. A laparoscopic surgical liver biopsy proce-
dure was performed by veterinary staff in a surgical suite at the 
CNPRC in overnight-fasted animals between 8:00 AM and 9:00 
AM. Animals were sedated with ketamine (5–30 mg/kg im), intu-
bated, and prepared for surgery. Anesthesia was maintained using 
inhalant anesthesia (1–3% isoflurane). A series of two to three 
small (1 cm) incisions were made through the skin and subcuta-
neous tissues into the abdomen. Laparoscopy tools were inserted 
to visualize the area of dissection, followed by introduction of a 
Veress needle and insufflation of the abdomen. Up to 10 (2–3 
mm cubed) small liver samples were extracted using biopsy for-
ceps and frozen in liquid nitrogen. Biopsy samples were aliquoted 
into three different tubes and snap-frozen in liquid nitrogen. The 
abdomen was closed using suture in two layers, and the animals 
were allowed to recover from anesthesia. For postoperative moni-
toring the monkeys were observed continuously until conscious, 
and then checked regularly until fully recovered by the CNPRC 
primate medicine staff. Animals were monitored postoperatively 
for signs of pain or bleeding for several days. Postoperative anal-
gesia employed buprenorphine 0.03 mg/kg administered twice 
daily by intramuscular injection and ketoprofen (5 mg/kg im, 
daily) for 3 days post procedure.
Measurement of metabolites, lipoproteins, and 
apolipoproteins
Plasma glucose concentrations were measured with a YSI glu-
cose analyzer (YSI Life Sciences). Plasma total cholesterol (TC), 
HDL-C, direct LDL-C, TG, ApoA1, ApoB, ApoC3, and ApoE con-
centrations were determined by using a Polychem chemistry ana-
lyzer (PolyMedCo) with reagents from MedTest DX (Canton, 
MI). VLDL-C was calculated by subtracting HDL-C and LDL-C 
from TC. Plasma concentrations of LDL-C and ApoB determined 
using these assays were highly correlated (R2 = 0.67 at baseline, 
R2 = 0.69 after 1 month, and R2 = 0.79 after 3 months of fructose 
consumption) and changes (s) of LDL-C and ApoB were also 
highly correlated at 1 month (R2 = 0.53) and 3 months (R2 = 0.59) 
post fructose consumption (supplemental Fig. S1), indicating 
that while ApoB was not increased in rhesus macaques on the 
high-fructose diet, this is not likely due to a lack of specificity or 
sensitivity of the assay used for ApoB. The lipoprotein particle size 
separation assays and the anti-apolipoprotein antibody assays 
were developed for use in human samples, and have not been 
specifically validated for use in monkey plasma.
Concentrations of VLDL, IDL, LDL, and HDL particle subfrac-
tions were further analyzed in specific particle-size intervals using 
ion mobility, which uniquely allows for direct particle quantifica-
tion as a function of particle diameter (22), following a procedure 
to remove other plasma proteins (23). The ion mobility instru-
ment utilizes an electrospray to create an aerosol of particles, 
which then pass through a differential mobility analyzer coupled 
to a particle counter. Particle concentrations (in nanomoles per 
liter) are determined for subfractions defined by the following 
size intervals: VLDL: large (42.40–54.70 nm), medium (33.50–
42.39 nm), small (29.60–33.49 nm); IDL: large (25.00–29.59 nm), 
small (23.33–24.99 nm); LDL: large (22.0–23.32 nm), medium 
(21.41–21.99 nm), small (20.82–21.40 nm), very small (18.0–20.81 
nm); HDL: large (10.50–14.50 nm); small (7.65–10.49 nm). Peak 
LDL diameter (in nanometers) was determined as previously de-
scribed (22).
Measurement of pancreatic and adipocyte hormones
Plasma adiponectin, insulin. and leptin concentrations were 
determined by RIA with assays from Millipore (Burlington, MA).
RNA-seq analysis of gene expression in liver biopsy 
samples
Total RNA was isolated from liver biopsies using the Norgen 
total RNA purification kit (Norgen Biotek, Thorold, ON, Canada). 
RNA quality was assessed by NanoDrop (ThermoFisher Scienc-
tific, Waltham, MA) and RNA integrity was measured by TapeSta-
tion software (Agilent Technologies, Santa Clara, CA). Sequencing 
libraries were generated using the Illumina TruSeq polyA+ sam-
ple prep kit and single-end sequenced (50 times) on the HiSeq 
platform. Sequencing reads were mapped to the human genome 
using STAR (v2.5.3a) and transcripts/genes were quantified using 
Salmon (v0.6.0). The mapping rate averaged 60% across all sam-
ples. Differential gene expression analysis was performed using 
DESeq2.
For quantitation using quantitative (q)RT-PCR, a high-capacity 
RNA to cDNA kit (Life Technologies, Grand Island, NY) was used 
for reverse transcription of RNA. Acetyl-CoA carboxylase (ACACA) 
gene expression quantitative PCR was performed using TaqMan 
assays per the manufacturer’s protocol on a Bio-Rad CFX96 
Touch real-time PCR detection system (Bio-Rad Laboratories, 
Richmond, CA). Reactions were performed in triplicate using 
RPS9 as the normalizer.
Statistical analysis
Descriptive statistics are provided for each of the outcomes as 
mean ± SEM. Analysis for significance used SPSS Statistic version 
24 (IBM). The effects of diet on each outcome parameter were 
initially compared with repeated measures nonparametric test 
(Friedman). Relationships between changes of TG, ApoC3, ApoE, 
and HOMA-IR were examined with simple and multivariate re-
gression analyses using log-transformed data.
For the effects of RNAi treatment with ARO-APOC3 on plasma 
ApoC3 and TG concentrations in animals with HFCS-induced hy-
pertriglyceridemia, we compared the mean of concentrations 
from day 43 to day 85 time points during which fasting plasma 
ApoC3 and fasting and nonfasting TG concentrations were stable 
versus day 8 (“baseline”). Paired t-tests were performed to deter-
mine the effects of ARO-APOC3 versus baseline pretreatment 
concentrations.
RESULTS
Effect of fructose consumption on body weight and 
metabolic outcomes
The effects of fructose consumption for 1 and 3 months 
on body weight and indices of glucose homeostasis (fasting 
glucose, insulin, and HOMA-IR), leptin, and adiponectin 
concentrations in rhesus macaques are summarized in 
Table 1. Rhesus macaques provided with fructose-sweetened 
beverages progressively increased weight over time (diet ef-
fect, P < 0.001). Overall, fructose consumption rapidly in-
duced a state of insulin resistance and changes of circulating 
adipokines that are indicative of disrupted metabolic ho-
meostasis. Rapid effects of diet were observed on fasting 
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insulin concentrations (P < 0.001) and HOMA-IR (P < 
0.01), suggesting the development of insulin resistance 
(Table 1). The increase of HOMA-IR was primarily the re-
sult of increased plasma insulin concentrations, with fast-
ing glucose concentrations exhibiting small but significant 
decreases (Table 1).
Leptin resistance and reduced adiponectin signaling 
contribute to metabolic dysfunction in obesity (24). Fast-
ing plasma leptin concentrations rapidly increased during 
fructose consumption, while fasting adiponectin concen-
trations declined at 1 and 3 months (Table 1). Increases of 
fasting leptin were correlated with weight gain after 3 
months of fructose consumption ( = 0.392, P < 0.01). 
However, the observed changes of indices of insulin resis-
tance (fasting plasma insulin or HOMA-IR) were not corre-
lated with baseline or fructose-induced changes of plasma 
leptin or adiponectin concentrations.
Effect of fructose consumption on plasma lipid and 
lipoprotein concentrations
Consumption of fructose-sweetened beverages pro-
duced marked increases of fasting TG and VLDL-C con-
centrations (Fig. 1A) (diet effect for both measurements, 
P < 0.001). Fasting TG concentrations increased by 
approximately 100% over baseline concentrations af-
ter 1 month of fructose consumption. VLDL-C levels 
increased approximately 70% over baseline concentra-
tions (Fig. 1B).
Fructose consumption increased circulating TC by 10% 
(P < 0.005). Small differences in HDL-C were also observed 
(diet effect, P < 0.05); however, HDL-C was not significantly 
changed compared with baseline after 3 months. Mean 
LDL-C concentrations were not significantly affected by 
consumption of the high-fructose diet.
For the apolipoproteins, the most marked effects of 
fructose intake were observed for ApoC3 and ApoE (diet 
effects, both P < 0.001). These responses to fructose con-
sumption were rapid and similar to the increases observed 
for TG and VLDL-C. Increases of ApoC3 and ApoE con-
centrations peaked after 1 month, with no further increases 
after 3 months of fructose consumption. Both ApoC3 and 
ApoE increased approximately 40% during the diet (Fig. 
1C, D), with strong correlations with each other ( = 0.501, 
P < 0.001). While the fructose-sweetened beverage had a 
significant effect on ApoA1 (P < 0.05), the effects were 
small and not consistent over time (Fig. 1C, D). Fructose 
consumption had no significant effect on plasma ApoB 
concentrations (Fig. 1C, D).
Fructose rapidly increases plasma lipoproteins in rhesus 
macaques
Type 2 diabetes and the metabolic syndrome (MetS) are 
associated with increased small dense LDL-C and large-di-
ameter TG-enriched VLDL-C levels (25). Fructose con-
sumption had significant effects to increase circulating 
levels of most lipoprotein particles fractionated by particle 
diameter (Table 2). Repeated measures analysis using 
pooled LDL, IDL, and VLDL data indicated significant ef-
fects of diet (LDL, P < 0.05; for IDL and VLDL, P < 0.001). 
However, proportionately, fructose consumption appears 
to have a greater impact to increase the larger lipoprotein 
particles (Fig. 1E).
Fasting TG concentrations were highly correlated with 
VLDL subfractions (Fig. 2A–C). Relationships between 
VLDL-C and VLDL subfractions were not observed in 
chow-fed condition (Fig. 2D–F); however, VLDL-C exhib-
ited strong correlations with VLDL subfractions after 3 
months on the high-fructose diet (Fig. 2G–I). A robust re-
lationship also developed between fasting TG and VLDL-C 
concentrations during the 3 months of fructose consump-
tion (supplemental Fig. S2) ( = 0.356 at baseline,  = 0.647 
after 3 months, both P < 0.01). Indeed, fructose consump-
tion had similar effects to increase both fasting TG and 
VLDL-C concentrations (Fig. 1B). Increases () of circulat-
ing TG and VLDL-C levels were also highly correlated after 
1 and 3 months of fructose consumption ( = 0.73 and 
0.71, P < 0.01).
Correlation between fructose-induced 
hypertriglyceridemia and ApoC3
We next used simple and multiple regression modeling 
to identify variables closely related to fructose-induced in-
creases of fasting TG, IDL, and VLDL particles after 1 and 
3 months of fructose consumption. Independent variables 
used in the analysis were initially selected based on indices 
of glucose and lipid homeostasis exhibiting physiologi-
cally significant responses to diet (Table 1, Fig. 1C). Base-
line values were included in the model to assess whether 
TABLE 1. Impact of dietary supplementation with fructose on body weight and indices of glucose homeostasis
Prefructose  
Measurement
1 Month Fructose Measurement  
(Change)
3 Months Fructose Measurement  
(Change) Diet Effect*
Body weight (kg) 15.9 ± 0.3 16.7 ± 0.3a (+0.8 ± 0.1) 17.5 ± 0.3b (+1.6 ± 0.1**) P < 0.001
Glucose (mg/dl) 80 ± 2 78 ± 2 (2 ± 2) 77 ± 2 (3 ± 2) P < 0.05
Insulin (/ml) 66 ± 7 109 ± 15c (+44 ± 111) 129 ± 26d (+63 ± 195) P < 0.001
HOMA-IR 13.2 ± 1.4 21.5 ± 3.2c (+8.4 ± 3.1) 25.2 ± 5.5d (+12.1 ± 5.4) P < 0.01
Leptin (ng/ml) 19.7 ± 1.5 23.1 ± 1.6e (+3.3 ± 0.6) 24.8 ± 1.6f (+5.0 ± 0.9*) P < 0.001
Adiponectin (g/ml) 9.3 ± 1.0 6.7 ± 0.7e (2.6 ± 0.4) 6.1 ± 0.6f (3.2 ± 0.6*) P < 0.001
In the third and fourth columns, changes in concentration (Conc.) are in parentheses. The significance 
between measurements before and during fructose consumption determined using post hoc comparisons are 
indicated by superscript letters: aP < 0.001 versus prefructose, 3 months fructose; bP < 0.001 versus prefructose, 1 
month fructose; cP < 0.01 versus prefructose; dP < 0.05 versus prefructose; eP < 0.001 versus prefructose, P < 0.05 
versus 3 months fructose; fP < 0.001 versus prefructose, P < 0.05 versus 1 month fructose. 
*P  0.05, significant difference between deltas at 1 and 3 months.
**P < 0.001, significant difference between deltas at 1 and 3 months.
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Fig. 1. Impact of dietary supplementation with fructose on lipid profiles. A: Fasting concentrations of TG, TC, HDL-C, LDL-C, and VLDL-C. 
B: Percent increase above baseline after 1 and 3 months of fructose consumption for the measures shown in panel A. C: Fasting concentra-
tions of apolipoproteins. D: Percent increase above baseline after 1 and 3 months of fructose consumption for the measures shown in panel 
B. E: Percent increase above baseline after 1 and 3 months of fructose consumption for lipoproteins subfractionated by particle diameter. 
Significant differences are indicated by asterisks: significant differences of 1 and 3 month values from baseline, or by lines between specific 
time points, are indicated; ***P < 0.001; **P < 0.01; *P < 0.05. Statistics for actual values for the data in E are provided in Table 2.
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baseline conditions also correlated with fructose-induced 
increases of fasting plasma TG concentrations in the model. 
The independent variables were baseline (prefructose) 
and s for body weight, glucose, insulin, HOMA-IR, leptin, 
adiponectin, ApoC3, and ApoE.
For increases of fasting plasma TG, the selected variables 
explained 62.3% of the variation after 1 month and 51.6% 
after 3 months of fructose consumption (Table 3) (R2 = 
0.62 after 1 month, P < 0.001; R2 = 0.52 after 3 months, P = 
0.004). Increases in plasma concentrations of ApoC3, but 
not ApoE, exhibited a strong association with increases in 
TG at both time points in the model (Fig. 3A, B). Modeling 
for fructose-induced increases of fasting plasma total IDL 
or VLDL particles in animals fed fructose was less success-
ful and not consistent at the 1 and 3 month time points. 
Modeling for changes in VLDL particles after 1 month of 
fructose explained 50% of the variability (R2 = 0.501, P < 
0.01); ApoC3 and adiponectin are significant variables 
in the model (P = 0.001 for ApoC3, P < 0.05 for 
adiponectin). Modeling was successful in partially calcu-
lating increases of IDL particles after 1 month of fructose 
consumption (R2 = 0.471, P < 0.05).
ApoC3 RNAi reverses fructose-induced 
hypertriglyceridemia
An RNAi-based strategy was used to investigate whether 
reduction of circulating ApoC3 by inhibiting ApoC3 ex-
pression with an RNAi trigger targeting APOC3 mRNA 
(ARO-APOC3) would reduce hypertriglyceridemia result-
ing from consumption of a high-sugar (HFCS) diet. Ani-
mals provided two 500 ml beverages containing HFCS 
(15% by weight) and consuming a moderate fat diet (see 
the Materials and Methods) rapidly developed elevated 
fasting plasma ApoC3 concentrations and fasting hypertri-
glyceridemia (Fig. 4). Fasting TG concentrations increased 
by more than 3-fold, from 87 ± 23 mg/dl to 316 ± 91 mg/dl 
( = +177 ± 80 mg/dl; P < 0.05, n = 6). Nonfasting TG con-
centrations also increased from 158 ± 38 mg/dl to 523 ± 
196 mg/dl ( = +365 ± 163 mg/dl; P < 0.05). Fasting ApoC3 
concentrations increased by 50%, from 5.9 ± 0.3 mg/dl 
to 8.8 ± 1.9 mg/dl (n = 6).
In the four animals treated with injections of ARO-
APOC3, there was a rapid decline in fasting plasma ApoC3 
concentrations from 10.0 ± 2.8 mg/dl to 3.2 ± 0.5 mg/dl 
( = 6.8 ± 2.4 mg/dl; P < 0.025) during days 43–85 after 
the first injection of ARO-APOC3 (Fig. 4A), with levels fall-
ing by 65 ± 4% from pretreatment levels (P < 0.001, days 
43–85 vs. “baseline” pretreatment values at day 8) (Fig. 4B). 
Fasting TG concentrations declined significantly during days 
43–85 following the first injection from 310 ± 140 mg/dl to 
118 ± 38 mg/dl (% = 48.5 ± 13.0%; P < 0.025) and non-
fasting TG concentrations decreased from 620 ± 293 mg/dl 
to 220 ± 71 mg/dl (% = 55.7 ± 9.0; P < 0.005) at days 56 
and 84 posttreatment. The decreases of TG levels were 
most pronounced in animals with the most marked degree 
of pretreatment hypertriglyceridemia (Fig. 4C, D). In the 
other two animals on the moderate fat plus HFCS diet that 
were treated with vehicle, fasting ApoC3, fasting TG, and 
nonfasting TG concentrations were unchanged from base-
line pretreatment levels (data not shown).
FO supplementation produces a rapid and sustained  
shift of lipoprotein particle distribution away from IDL 
and VLDL
Supplementation with FO (4 g/day) attenuates the fructose-
induced increases of both TG and ApoC3 concentrations 
TABLE 2. Impact of dietary supplementation with fructose on plasma concentrations (nmol/L) of lipoprotein 
fractionated by particle diameter
Prefructose  
Measurement
1 Month Fructose Measurement  
(Change in Conc.)
3 Months Fructose Measurement  
(Change in Conc.) Diet Effect
HDL III and IIa 16,774 ± 258 19,360 ± 355a (2,586 ± 330) 18,597 ± 316a (1,823 ± 299) P < 0.001
HDL IIb 8,610 ± 223 9,359 ± 239b (748 ± 223) 8,980 ± 257b (370 ± 226) P < 0.05
MidZone 966 ± 21 1,046 ± 27a (79 ± 21) 1,013 ± 24 (44 ± 24) P < 0.005
LDL IVc 68 ± 2 82 ± 3a (14 ± 2) 77 ± 2a (9 ± 2) P < 0.001
LDL IVb 44 ± 1 51 ± 2a (6 ± 1) 50 ± 2a (6 ± 2) P < 0.001
LDL IVa 44 ± 2 42 ± 2 (1 ± 2) 48 ± 3 (4 ± 3) n.s.
LDL IIIb 38 ± 2 36 ± 3 (2 ± 2) 43 ± 3c (5 ± 3) P < 0.05
LDL IIIa 86 ± 4 88 ± 6 (2 ± 6) 100 ± 7d (14 ± 6) P < 0.05
LDL IIb 88 ± 4 94 ± 5 (6 ± 5) 97 ± 5 (9 ± 5) n.s.
LDL IIa 75 ± 3 83 ± 3 (8 ± 4) 79 ± 3 (4 ± 3) P < 0.05
LDL I 113 ± 4 128 ± 5e (16 ± 5) 117 ± 5 (5 ± 4) P < 0.05
IDL II 107 ± 5f 139 ± 6f (31 ± 6) 121 ± 5f (14 ± 4) P < 0.001
IDL I 82 ± 4f 121 ± 7f (39 ± 6) 107 ± 5f (25 ± 4) P < 0.001
VLDL-Sm 27 ± 1f 43 ± 3f (16 ± 2) 38 ± 2f (11 ± 1) P < 0.001
VLDL-Int 19 ± 1g 34 ± 3g (15 ± 3) 30 ± 3g (11 ± 2) P < 0.001
VLDL-Lg 8 ± 1 17 ± 2a (9 ± 2) 15 ± 2a (7 ± 1) P < 0.001
In the third and fourth columns, changes in concentration (Conc.) are in parentheses. n.s., not significant.
aP < 0.001, significantly different from prefructose.
bP < 0.01, significantly different from prefructose.
cP < 0.001, significantly different from 1 month fructose.
dP < 0.05 versus prefructose, P < 0.01 versus 1 month; significantly different from prefructose and 1 month fructose.
eP < 0.01 versus prefructose, P < 0.05 versus 3 months; significantly different from prefructose and 3 months fructose.
fP < 0.01; values significantly different at all times measured.
gP < 0.001 (prefructose vs. 3 months), P < 0.05 (1 month vs. 3 months); values significantly different at all times 
measured.
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(22). In the current study, we also observed that FO re-
versed the marked fructose-induced shift of lipoprotein 
particle size toward IDL and VLDL (Fig. 5A, B). While fruc-
tose consumption nearly doubled the concentration of 
large VLDL particles (% = 95.4 ± 35.6%; P < 0.03) in nine 
control animals after 6 months on the high-fructose diet, 
VLDL-Lg actually decreased significantly in the 10 animals 
that received FO (% = 25.4 ± 7.4; P < 0.005 vs. control), 
Fig. 2. Relationships between TG, VLDL-C, and VLDL subfractions at baseline (chow-fed) and after 3 months of fructose consumption. 
A–C: Relationships between TG and small (A), intermediate (B), and large (C) VLDL subfractions. D–F: Weak relationships between VLDL-C 
and small (D), intermediate (E), and large (F) VLDL subfractions at baseline. Relationships between VLDL-C and VLDL subfractions is 
stronger after 3 months of fructose consumption. G–I: VLDL-C and small (G), intermediate (H), and large (I) subfractions. Units for TG 
and VLDL-C are milligrams per deciliter, subfractions are nanomoles per liter.
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despite sustained consumption of fructose. Similar results 
were also observed earlier at the 1 and 3 month time points 
in the monkeys consuming fructose along with FO com-
pared with those consuming fructose alone (Fig. 5C–E). 
The lipoprotein particle distribution in the fructose-fed 
animals supplemented with FO was shifted from IDL and 
VLDL primarily to intermediate-sized LDL particles.
The effect of FO supplementation was further assessed 
in liver biopsies obtained from a separate group of rhesus 
macaques (n = 4/group). Analysis of liver gene expression 
by RNA-seq indicated significant changes of hepatic gene 
expression in animals fed the moderate-fat diet plus HFCS-
sweetened beverages plus FO, as opposed to the HFCS diet 
with the blended soybean and canola control oil (see the 
supplemental data). Using P < 0.05 as the selection criteria, 
269 upregulated and 307 downregulated transcripts were 
identified. Pathway analysis of genes that were downregu-
lated identified “activation of gene expression by SREBF 
(SREBP)” and “regulation of cholesterol synthesis by 
SREBP (SREBF)” as being highly significant (P value 6.81 × 
1010, 3.81 × 108) (Table 4). This group of genes included 
enzymes involved in fatty acid synthesis [e.g., ACACA and 
FASN], as well as genes critical for cholesterol synthesis 
(HMGCR) and lipoprotein metabolism [PCSK9, LDL re-
ceptor (LDLR)]. The effects of FO supplementation on 
the expression of ACACA, encoding ACACA  that cata-
lyzes the carboxylation of acetyl-CoA to malonyl-CoA (the 
rate-limiting step in de novo lipogenesis), and the gene 
that was most significantly downregulated in the RNA-seq 
analysis were confirmed using qRT-PCR in a larger cohort 
(2-fold, P = 0.006, n = 7) (Fig. 6).
DISCUSSION
The results from this study provide further evidence of a 
strong correlation between plasma ApoC3 concentrations 
and fructose-induced elevations of circulating TG-rich 
VLDL-C. They also further support the use of the fructose-fed 
rhesus macaque as a relevant nonhuman primate model of 
diet-induced MetS, and in particular the dyslipidemic and 
TABLE 3. Multivariate linear regression results for predictors of 
fructose-induced changes () in fasting plasma concentrations of TG
Dependent Variable:  TG
Variables entered: 1 Month Fructose 3 Months Fructose
Apoc3 (baseline) 0.671 0.536
Apoc3 <0.001 0.002
Apoe (baseline) 0.866 0.429
ApoE 0.820 0.343
Insulin (baseline) 0.419 0.463
lnsulin 0.316 0.029
Glucose (baseline) 0.445 0.457
Glucose 0.283 0.022
HOMA-IR (baseline) 0.422 0.466
HOMA-IR 0.330 0.030
Leptin (baseline) 0.001 0.771
Leptin 0.009 0.076
Body weight (baseline) 0.586 0.604
Body weight 0.541 0.995
Adiponectin (baseline) 0.380 0.738
Adiponectin 0.085 0.518
Significant values are in bold text. Modeling explained 62% of the 
variability in fructose-induced increase in TG after 1 month (R2 = 0.623, 
P < 0.001) and 52% after 3 months (R2 = 0.516, P = 0.004).
Fig. 3. Increases in plasma concentrations of TG 
with fructose consumption are correlated with in-
creases of ApoC3 (A) but not ApoE (B). Data are 
log-transformed.
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insulin resistance components of MetS (18–20). Rhesus 
macaques that are provided fructose as a flavored beverage 
rapidly enter a state of positive energy balance and exhibit 
symptoms of MetS. Large increases of fasting plasma insu-
lin and TG concentrations are observed after only 1 month 
of fructose consumption.
Recent studies in mouse models suggest that the small 
intestine is a major site of fructose disposal, where it is con-
verted to glucose, lactate, glycerate, and organic acids (26). 
However, the intestine appears to have an upper limit for 
metabolizing fructose, with higher doses resulting in sig-
nificant levels of fructose accumulating in the liver or me-
tabolized by colonic microbiota. In the liver, fructose 
increases de novo lipogenesis as it bypasses a key regulatory 
point in glycolysis (27). The results from the current study 
are consistent with fructose consumption increasing circu-
lating levels of large TG-rich VLDL particles in rhesus ma-
caques. Increased rates of de novo lipogenesis are likely to 
contribute to this effect (27, 28); although the increases of 
ApoC3 suggest that reduced clearance of TG-rich remnant 
lipoproteins may also contribute.
A strong association between fasting plasma VLDL-C con-
centrations with VLDL-Lg, and with TG, suggests that large 
VLDL particles are enriched with both TG and cholesterol 
esters. In humans, supplementing the diet with fructose 
beverages has a dose-dependent effect to modestly but sig-
nificantly increase LDL-C (28–30). In the current study, 
fructose consumption was associated with a modest (10%) 
increase of TC, but no significant change in LDL-C levels. 
While there was a significant change in HDL-C concentra-
tions, the magnitude of the effect was very small (<5%) and 
not consistent between the 1 and 3 month time points. While 
plasma concentrations of total LDL-C did not increase dur-
ing fructose consumption, there were significant increases 
of small dense LDL particles measured using ion mobility. 
The discrepancy between the two measurements is sugges-
tive of accumulation of TG in lipoprotein remnant particles.
It is also worth noting that, while ApoA1 and ApoB con-
centrations did not exhibit major increases in the group as 
a whole, ApoA1 and ApoB correlated with fructose- 
induced changes in TC levels in individual animals (ApoB, 
P < 0.001; ApoA1, P < 0.05). Strong correlations were also 
observed between ApoB and LDL-C (P = 0.001). The 
current study focused on the changes in plasma TG con-
centration with fructose consumption, with the majority 
(56/59) of animals exhibiting increases of plasma TG con-
centrations during 3 months of fructose consumption. 
There was significant variation between animals in how 
Fig. 4. Suppression of ApoC3 using RNAi reverses hypertriglyceridemia induced by HFCS. Adult male rhesus macaques (n = 4) were pro-
vided 500 ml of a HFCS beverage (15% by weight) twice daily. Fasting plasma samples were collected at the times indicated and assayed for 
ApoC3 (A, B) or TG (C, D). Data shown are actual values (A, C) or percent baseline (34 days of HFCS). After 42 days, the animals received 
a single subcutaneous injection of ApoC3-RNAi (4 mg/kg) on study days 0 and 29 (indicated by arrows).
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fructose consumption affects cholesterol metabolism. This 
variation may be explained by genetic differences between 
animals resulting in the differences in differential expres-
sion of genes regulating cholesterol homeostasis.
A significant finding of this study is the observation that 
increases of circulating ApoC3 concentrations correlate 
consistently with fructose-induced hypertriglyceridemia. 
While insulin resistance is often associated with dyslipidemia, 
Fig. 5. A FO dietary supplement alters the effects of fructose on the distribution of lipoprotein particles. A: Increases in lipoprotein parti-
cles in rhesus macaques provided fructose (n = 9). The data shown are percent increases above baseline (chow-fed) condition (%). B: In-
creases in lipoprotein particles in rhesus macaques provided fructose and FO (n = 10). In panels C–E, %s are compared between fructose 
only (Con) and fructose+FO (FO) groups after 1 month (C), 3 months (D), or 6 months (E).
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indices of insulin resistance (insulin, HOMA-IR) did not 
exhibit strong associations with fructose-induced in-
creases in fasting plasma concentrations of TG and large 
TG-rich VLDL-C in modeling using linear regression.
There is evidence in humans that ApoC3 expression is a 
significant contributor to risk for CVD (7–9), while loss-of-
function mutations of ApoC3 are protective against the de-
velopment of CVD (5). In the current study, fructose 
TABLE 4. FO supplementation alters hepatic expression of genes involved in lipid metabolism.
Gene Symbol Fold Change [(HFCS+FO)/HFCS] 1/(Fold Change) P P (Adjusted)
Transcription factors
 SREBF1 0.72 1.39 0.035 1.000
 SREBF2 0.72 1.38 0.031 1.000
Fatty acid synthesis/metabolism
 ACACA 0.50 1.98 1.35E-07 3.47E-04
 ACOT12 0.71 1.40 0.004 0.811
 ACSF3 0.67 1.50 0.001 0.446
 ACSL3 0.69 1.45 0.011 1.000
 ACSS2 0.71 1.40 0.036 1.000
 ELOVL5 0.74 1.35 0.022 1.000
 FABP4 0.62 1.61 0.000 0.238
 FADS1 0.60 1.68 0.001 0.475
 FADS2 0.74 1.36 0.018 1.000
 FASN 0.65 1.53 0.007 0.972
Cholesterol synthesis/metabolism
 ABCG8 0.79 1.26 0.033 1.000
 DHCR7 0.69 1.45 0.021 1.000
 FDFT1 0.67 1.49 0.001 0.304
 FDPS 0.54 1.85 0.000 0.033
 HMGCR 0.66 1.51 0.006 0.932
 HMGCS1 0.57 1.76 0.000 0.238
 IDI1 0.65 1.55 0.006 0.931
 LSS 0.68 1.46 0.017 1.000
 MVD 0.66 1.51 0.009 0.997
 SC5D 0.73 1.37 0.027 1.000
Lipoprotein metabolism
 PCSK9 0.64 1.57 0.005 0.895
 LDLR 0.70 1.42 0.026 1.000
 LRP4 0.72 1.40 0.037 1.000
 APOC2 0.72 1.38 0.033 1.000
 APOL3 1.47 0.68 0.010 1.000
 APOL4 1.49 0.67 0.012 1.000
CYP enzymes
 CYP1B1 0.46 2.16 0.000 0.001
 CYP21A2 0.62 1.62 0.001 0.446
 CYP2B6 0.75 1.33 0.030 1.000
 CYP51A1 0.53 1.90 0.000 0.062
Data are expressed as fold change in animals fed HFCS and FO (HFCS+FO) relative to animals provided the 
HFCS and control oil.
Fig. 6. A FO dietary supplement significantly reduces 
liver ACACA expression. A: KEGG pathway enrich-
ment analysis for hepatic genes significantly (adjusted 
P < 0.05) downregulated by FO compared with control 
(sunflower oil). B: ACACA expression (DESeq2 nor-
malized counts) by RNA-seq analysis in control and 
FO treatment conditions (n = 4/group). C: CYP1B1 
expression (DESeq2 normalized counts) by RNA-seq 
analysis in control and FO treatment conditions (n = 
4/group). D: Validation of the ACACA expression by 
qRT-PCR in control and FO (n = 7/group). Error bars 
represent SEM. *P < 0.05; ***P < 0.01.
 at Carlson Health Sci Library, on April 16, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2019/02/05/jlr.M089508.DC1
Supplemental Material can be found at:
816 Journal of Lipid Research Volume 60, 2019
consumption rapidly (within 1 month) increases fasting 
plasma ApoC3 concentrations. Plasma ApoC3 concentrations 
also increase dose-dependently after only 2 weeks of 
consuming dietary sugar (HFCS) in humans (29). The re-
lationship between plasma total and lipoprotein choles-
terol and risk for CVD in rhesus macaques has not been 
well studied. However, atherosclerosis has been observed 
in rhesus macaques fed high-fat diets (31). However, it is 
important to note that similar changes in ApoC3 and TG 
have been associated with decreased or increased risk for 
CVD in humans (5, 7–9).
Fructose-induced changes of ApoE and ApoC3 concen-
trations were highly correlated. The C-terminal region of 
ApoE contributes to the regulation of TG-rich lipoprotein 
clearance by functioning as a LDLR-binding site (32). 
ApoC3 affects the uptake of TG-rich lipoproteins by the 
LDLR and LDLR-related protein 1 (LRP1) (33). However, 
increases in ApoC3 but not ApoE were strongly associated 
with fructose-induced hypertriglyceridemia. The signifi-
cance of this observation is unclear but suggests that of the 
two apolipoproteins, the functions of ApoC3 are the pre-
dominant variable driving changes in circulating TG 
concentrations. We were also able to demonstrate that 
suppression of ApoC3 synthesis, using RNAi methodology, 
reversed hypertriglyceridemia in animals maintained on a 
moderate-fat diet and consuming HFCS-sweetened bever-
ages two times a day. These initial data from n = 4 animals 
suggest a mechanistic link between circulating ApoC3 
and TG concentrations because specific reductions of 
ApoC3 with RNAi lead to an amelioration of fasting hyper-
triglyceridemia resulting from the consumption of a high-
sugar diet. Postprandial TGs were also measured in the 
RNAi experiment, and exhibited similar responses to 
ARO-APOC3.
The mechanisms linking ApoC3 to adverse effects on 
lipid metabolism remain controversial. Results from early 
studies in ApoC3 transgenic mice suggested reduced cel-
lular uptake of TG-rich particles (11). Additional studies 
indicated that ApoC3 inhibits LPL (34–37); at higher con-
centrations, ApoC3 also appears to inhibit hepatic lipase 
(38). Reductions of TG observed with volanesorsen treat-
ment are independent of effects on LPL (12). A hypothesis 
is that ApoC3 increases TG levels by affecting uptake of 
TG-rich lipoproteins by the LDLR and LRP1 (33).
The effects of FO supplementation on changes of lipo-
protein particle size distribution in fructose-fed rhesus 
monkeys are novel and interesting. We have previously re-
ported that FO provided at a dose of 4 g/day largely pre-
vents the increases of both plasma ApoC3 and circulating 
TG concentrations in the fructose-fed rhesus monkey 
model of MetS (20), and EPA+DHA together have been 
shown to lower circulating ApoC3 in humans (39). It is 
likely that these effects are related, based on the strong as-
sociations between plasma concentrations of ApoC3 and 
TG in response to fructose feeding.
A previous study using rhesus macaques examined the 
effects of FO on lipid metabolism and dyslipidemia in-
duced by a diet supplemented with saturated fat and cho-
lesterol (2% cholesterol, 25% coconut oil) (40). In that 
study, FO reduced the number of VLDL, IDL, and LDL 
particles in plasma, and reduced cholesterol ester content 
of lipoproteins. In the current study, the impact of FO of 
fructose-induced hypertriglyceridemia appears to involve 
suppression of hepatic lipogenic enzymes. RNA-seq analysis 
suggests that FO supplementation reduces the activity of 
the SREBPF family of transcription factors known to drive 
expression of enzymes involved in fatty acid and choles-
terol synthesis and metabolism, particularly ACACA (41). 
These findings are generally consistent with results from 
experiments examining the impact of FO on hepatic gene 
expression in mice (42) and in primary cultured rat hepa-
tocytes (43). Reduced de novo lipogenesis is a plausible 
explanation for the reduction of VLDL-C levels observed in 
fructose-fed animals provided the FO dietary supplement. 
Inhibition of SREBF2-mediated transcription of the LDLR 
gene also provides a plausible explanation (reduced LDLR-
mediated clearance) for the accumulation of LDL-particles 
observed with FO treatment. FO supplementation also re-
duced the expression of cytochrome P450 (CYP)1B1. This 
member of the CYP superfamily is known to be important 
for regulating steroid and fatty acid metabolism, and has 
been suggested to be a potential target for the treatment of 
the metabolic diseases of obesity (44).
There are several mechanisms by which FO, and the 
omega-3 and furan fatty acids it contains, may produce low-
ering of TG concentrations and the shift away from large 
TG-rich lipoproteins. First, FO has been demonstrated to 
inhibit de novo lipogenesis in human subjects during over-
feeding of a high-fructose diet, and our gene expression 
data (e.g., reduced ACACA expression) support this con-
clusion. (45). This response may be mediated in part by the 
actions of omega-3 fatty acids (EPA and DHA) to down-
regulate genes involved in hepatic lipid biosynthesis, in-
cluding FASN (46). In addition, the actions of FO to 
prevent the fructose diet-induced increase of ApoC3 (20) 
may contribute to its effects to prevent and even reduce the 
increases of larger IDL and VLDL particles while increas-
ing the amount of smaller-sized LDL particles. This mecha-
nism would involve generating smaller-sized LDL particles 
via increased hydrolysis of TG from larger TG-rich VLDL 
and IDL particles due to enhanced lipase activity that is 
unrestrained by ApoC3.
In summary, the results from the present study provide 
a further compelling link between excess consumption of 
beverages sweetened with fructose-containing sugars and 
dyslipidemia as well as new information on the potential 
protective effects of FO and omega-3 fatty acids. They also 
support the use of the fructose- and HFCS-fed rhesus ma-
caques as a nonhuman primate model for preclinical stud-
ies evaluating novel therapies targeting dyslipidemia in 
general and ApoC3 in particular.
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